BR0102252B1 - Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso - Google Patents

Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Info

Publication number
BR0102252B1
BR0102252B1 BRPI0102252-0B1A BR0102252A BR0102252B1 BR 0102252 B1 BR0102252 B1 BR 0102252B1 BR 0102252 A BR0102252 A BR 0102252A BR 0102252 B1 BR0102252 B1 BR 0102252B1
Authority
BR
Brazil
Prior art keywords
angiotensin
pharmaceutical composition
controlled release
receptor antagonist
release system
Prior art date
Application number
BRPI0102252-0B1A
Other languages
English (en)
Other versions
BR0102252A (pt
Inventor
Millan Ruben Dario Sinisterra
Paula Washington Xavier De
Dos Santos Robson Augusto Souza
Frederic Jean Georges Frezard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to BRPI0102252-0B1A priority Critical patent/BR0102252B1/pt
Priority to JP2002578949A priority patent/JP4439814B2/ja
Priority to EP02713951A priority patent/EP1389106A1/en
Priority to CN028106814A priority patent/CN1523985B/zh
Priority to CA002444145A priority patent/CA2444145C/en
Priority to PCT/BR2002/000051 priority patent/WO2002080910A1/en
Priority to US10/474,640 priority patent/US7858597B2/en
Publication of BR0102252A publication Critical patent/BR0102252A/pt
Priority to US11/980,345 priority patent/US20080108575A1/en
Priority to JP2009272002A priority patent/JP2010047611A/ja
Priority to US12/977,402 priority patent/US8293723B2/en
Priority to US13/656,941 priority patent/US20130164341A1/en
Publication of BR0102252B1 publication Critical patent/BR0102252B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
BRPI0102252-0B1A 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso BR0102252B1 (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0102252-0B1A BR0102252B1 (pt) 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
PCT/BR2002/000051 WO2002080910A1 (en) 2001-04-10 2002-04-09 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
EP02713951A EP1389106A1 (en) 2001-04-10 2002-04-09 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
CN028106814A CN1523985B (zh) 2001-04-10 2002-04-09 用于治疗高动脉压、其它心血管疾病和它的并发症的血管紧张素iiat1受体拮抗剂的制剂的制备
CA002444145A CA2444145C (en) 2001-04-10 2002-04-09 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illness and its complications
JP2002578949A JP4439814B2 (ja) 2001-04-10 2002-04-09 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンｉｉａｔ１受容体拮抗薬製剤の調製
US10/474,640 US7858597B2 (en) 2001-04-10 2002-04-09 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
US11/980,345 US20080108575A1 (en) 2001-04-10 2007-10-31 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
JP2009272002A JP2010047611A (ja) 2001-04-10 2009-11-30 動脈性高血圧症、他の心血管疾患、及びその合併症を治療するためのアンギオテンシンｉｉａｔ１受容体拮抗薬製剤の調製
US12/977,402 US8293723B2 (en) 2001-04-10 2010-12-23 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
US13/656,941 US20130164341A1 (en) 2001-04-10 2012-10-22 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0102252-0B1A BR0102252B1 (pt) 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Publications (2)

Publication Number Publication Date
BR0102252A BR0102252A (pt) 2003-01-21
BR0102252B1 true BR0102252B1 (pt) 2013-10-22

Family

ID=3947403

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0102252-0B1A BR0102252B1 (pt) 2001-04-10 2001-04-10 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Country Status (7)

Country Link
US (4) US7858597B2 (pt)
EP (1) EP1389106A1 (pt)
JP (2) JP4439814B2 (pt)
CN (1) CN1523985B (pt)
BR (1) BR0102252B1 (pt)
CA (1) CA2444145C (pt)
WO (1) WO2002080910A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
WO2003093262A2 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Processes for preparing losartan and losartan potassium
KR100554156B1 (ko) 2003-07-26 2006-02-22 학교법인 포항공과대학교 쿠커비투릴 유도체가 응집되어 형성된 나노 입자, 그 나노입자에 약물이 담지된 약제학적 조성물, 및 이들의 제조방법
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
WO2006087394A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
WO2008052295A1 (en) * 2006-10-30 2008-05-08 Universidade Federal De Minas Gerais Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products
WO2008089532A1 (en) * 2007-01-26 2008-07-31 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
CN101888829A (zh) * 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
EA038755B1 (ru) 2015-11-12 2021-10-14 Грейбаг Вижн, Инк. Агрегирующие микрочастицы для обеспечения замедленного высвобождения терапевтического агента для внутриглазной доставки
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS6025967A (ja) 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US5256687A (en) 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5210079A (en) 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03275617A (ja) * 1990-03-22 1991-12-06 Teikoku Seiyaku Co Ltd サイクロデキストリン類包接生理活性物質含有ポリ乳酸類マイクロスフェア及びその製造方法
IL100917A0 (en) * 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HU209658B (en) * 1992-02-21 1994-10-28 Cyclolab Kft Process for producing cyklodextrin inclusion compexes of fatty acids and their alkalimetal salts, as well as aqueous solutions of the complexes, and microbiological culture medium containing the complexes
AT399718B (de) 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5266583A (en) 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
ATE183641T1 (de) * 1992-12-23 1999-09-15 Saitec Srl Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen
CA2161225C (en) * 1993-04-22 2003-07-01 Sinil Kim Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5728402A (en) 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) 1995-06-19 1995-06-19 Astra Ab Novel medical use
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE69711068T2 (de) 1996-10-29 2002-09-12 Merck & Co Inc Verfahren zur kristallisation von losartan
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
ES2154191B1 (es) 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
FR2787330A1 (fr) 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
ATE487491T1 (de) * 1999-02-19 2010-11-15 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6178349B1 (en) 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
IT1307265B1 (it) 1999-08-09 2001-10-30 P F C Italiana Srl Speciality Procedimento per la preparazione di prodotti intermedi nella sintesidi lisinopril.
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso

Also Published As

Publication number Publication date
JP2004525167A (ja) 2004-08-19
US8293723B2 (en) 2012-10-23
CA2444145A1 (en) 2002-10-17
EP1389106A1 (en) 2004-02-18
CA2444145C (en) 2009-11-10
US20040171584A1 (en) 2004-09-02
BR0102252A (pt) 2003-01-21
US20080108575A1 (en) 2008-05-08
JP4439814B2 (ja) 2010-03-24
CN1523985B (zh) 2010-05-12
CN1523985A (zh) 2004-08-25
US7858597B2 (en) 2010-12-28
US20110091541A1 (en) 2011-04-21
US20130164341A1 (en) 2013-06-27
JP2010047611A (ja) 2010-03-04
WO2002080910A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
BR0102252B1 (pt) Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
BR0116659B1 (pt) Composição para uso em sistema de distribuição trasdérmica de droga e sistema de distribuição transdérmica de droga
BRPI0212137A2 (pt) diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
HUP0303081A3 (en) Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
HUP0303339A3 (en) Heteroaryl urea neuropeptide y y5 receptor antagonists, their use and pharmaceutical compositions containing them
NO20052285D0 (no) Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
AR028372A1 (es) Dispositivos de administracion de drogas de liberacion sostenida, metodos de uso y metodos de fabricacion de los mismos
TW200740459A (en) Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker
DK1307457T3 (da) Azabicycliske forbindelser, deres fremstilling og deres anvendelse som medikamenter, især som antibakterielle midler
PT1303261E (pt) Sistema para administracao de drogas auto-emulsionaveis, para drogas lipofilas extremamente insoluveis em agua
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
DE60135273D1 (de) Geschmacksmaskierte pharmazeutische Partikel
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
PT102854A (pt) Sistema de aplicacao de medicamento bioadesivo
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
ATE468324T1 (de) Pharmazeutische zusammensetzung
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
ECSP066486A (es) Antagonistas de receptores de acetilcolina muscarínicos ii
HN2002000150A (es) Agentes antibacteriano
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
PT1237559E (pt) Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
NO20024194L (no) Nytt selvemulgerende legemiddelavleveringssystem
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61P 9/12, A61P 9/00, A61K 31/724

Ipc: A61K 47/40 (2009.01), A61K 47/30 (2009.01), A61K 9

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 38 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE